Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors

Next Previous
Trial Profile

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raludotatug deruxtecan (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REJOICE-PanTumor01
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 22 May 2025 According to Daiichi Sankyo Company media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25)
  • 11 Mar 2025 Status changed from not yet recruiting to recruiting.
  • 04 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top